Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150160 | 0.81 | — | — | |
| SCHEMBL6386579 | 0.79 | KDM1A (0.30) | KDM1A | |
| SCHEMBL620862 | 0.78 | KDM4E (0.31) | — | |
| SCHEMBL6514980 | 0.77 | KDM1A (0.32) | KDM1A | |
| SCHEMBL6542690 | 0.73 | — | — | |
| SCHEMBL6512660 | 0.73 | — | — | |
| SCHEMBL3992251 | 0.70 | KDM1A (0.36) | KDM1A | |
| SCHEMBL1153469 | 0.68 | KDM1A (0.44) | KDM1A | |
| SCHEMBL734440 | 0.67 | KDM1A (0.38) | KDM1A | |
| SCHEMBL13818654 | 0.67 | KDM1A (0.34) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900657-B1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2621929-A1 | NOVEL ACRIDINE DERIVATIVES | Pharminox Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012175991-A1 | FUSED PENTACYCLIC ANTI - PROLIFERATIVE COMPOUNDS | PHARMINOX LIMITED (GB) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012042265-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1259475-A4 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | UNIV YALE (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1259475-A1 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | YALE UNIVERSITY (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064620-A1 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | YALE UNIVERSITY (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | TERT, NAT10, POT1 | KDM1A 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.